Clinical trials: CTLA4
Advanced Melanoma
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose…
- Trial name
- NCT06264180
- Testing
- Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab
- Where
- 81 sites in United States, France and 5 more
- Volunteers
- 400 people
- Sponsor
- Replimune, Inc.